

Appendix 4E

Preliminary final report

1. Details of reporting period

Name of entity	Cynata Therapeutics Limited (the Company)
ABN	98 104 037 372
Reporting Period	Year ended 30 June 2026
Previous Corresponding Period	Year ended 30 June 2025
Presentation Currency	Australian Dollars (\$)

2. Results for announcement to the market

Key information	30 June 2026 \$	30 June 2025 \$	Increase/ (decrease) %	Amount change \$
Revenues from ordinary activities	1,791,103	2,112,839	(15.23)	(321,736)
Loss from ordinary activities after tax attributable to members	9,089,281	9,390,586	(3.21)	(301,305)
Net loss for the period attributable to members	9,089,281	9,390,586	(3.21)	(301,305)
Net tangible (deficiency)/asset per share	(0.003)	0.018	-	-

3. Consolidated statement of profit or loss and other comprehensive income

Refer to attached consolidated financial statements.

4. Consolidated statement of financial position

Refer to attached consolidated financial statements.

5. Consolidated statement of cash flows

Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

Refer to attached consolidated financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

Not applicable.

9. Details of entities over which control has been gained or lost during the period

Not applicable.

10. Details of associate and joint venture entities

Not applicable.

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached consolidated financial statements.

12. Foreign entities

Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

Cynata Therapeutics Limited ("Cynata" or the "Company") and its controlled entities ("the Group") incurred a net loss from operations for the financial year ended 30 June 2026 of \$9,089,281 (2025: \$9,390,586) after accounting for an R&D refund of \$1,711,618 (2025: \$1,885,140). At 30 June 2026, the Group had a cash balance of \$897,418 (2025: \$5,049,744) and net liabilities of \$394,240 (2025: net assets of \$5,981,735). The net cash outflow from operating activities for the financial year was \$6,735,676 (2025: \$8,720,335). On 17 June 2026, the Company announced the primary evaluation results of the Phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD). While there were no safety concerns identified, with a similar adverse event profile between groups, there were also no significant differences between the control and active groups in the primary or key secondary efficacy endpoints. On 19 June 2026, the Company received top-line results of this trial from USYD. Again, there were no safety concerns identified, with a similar adverse event profile between groups. However, there were also no statistically significant differences between the active and control groups in either of the co-primary endpoints, which assessed pain reduction and change in cartilage thickness, respectively, from baseline to 24 months. There was a substantial and durable reduction in knee pain intensity at all timepoints from 3-24 months compared to baseline (secondary endpoint), but no significant differences between groups at any timepoint.

For more information, including subsequent events to balance date, refer to the attached consolidated financial statements.

14. Audit

This preliminary final report is based on accounts which are in the process of being audited. It is likely that the Auditor will issue an Independent Auditor's Report that will contain an 'Emphasis of Matter' paragraph drawing attention to a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern. The attached preliminary final report has been prepared on a going concern basis. Please refer to note 2 Going Concern.



Dr Geoff Brooke
Non-Executive Chair
31 August 2026

Contents

Consolidated statement of profit or loss and other comprehensive income	1
Consolidated statement of financial position	2
Consolidated statement of changes in equity	3
Consolidated statement of cash flows	4
Notes to the consolidated financial statements	5

Consolidated statement of profit or loss and other comprehensive income for the year ended 30 June 2026

		Year ended	
		30 June 2026	30 June 2025
	Note	\$	\$
Interest income		79,485	227,699
Other income		1,711,618	1,885,140
Total revenue and other income		1,791,103	2,112,839
Product development costs	3	(5,381,298)	(7,398,004)
Employee benefits expenses		(1,848,277)	(2,067,760)
Amortisation expenses	4	(260,313)	(282,964)
Impairment expenses	4	(1,353,626)	-
Share based payment expenses		(129,930)	(260,415)
Other expenses		(1,906,940)	(1,494,282)
(Loss) before income tax		(9,089,281)	(9,390,586)
Income tax expense		-	-
(Loss) for the year		(9,089,281)	(9,390,586)
Other comprehensive income, net of income tax			
Items that will not be reclassified subsequently to profit or loss		-	-
Items that may be reclassified subsequently to profit or loss			
Exchange differences on translating foreign operations		-	-
Other comprehensive income for the year, net of income tax		-	-
Total comprehensive loss for the year		(9,089,281)	(9,390,586)
(Loss) for the year attributable to:			
Owners of Cynata Therapeutics Limited		(9,089,281)	(9,390,586)
Total comprehensive loss for the year attributable:			
Owners of Cynata Therapeutics Limited		(9,089,281)	(9,390,586)
(Loss) per share:			
Basic and diluted (cents per share)		(3.84)	(4.58)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Consolidated statement of financial position as at 30 June 2026

	Note	30 June 2026 \$	30 June 2025 \$
Current assets			
Cash and cash equivalents		897,418	5,049,744
Trade and other receivables		70,546	104,650
Prepayments		151,672	194,618
Total current assets		1,119,636	5,349,012
Non-current assets			
Intangibles	4	234,965	1,848,904
Total non-current assets		234,965	1,848,904
Total assets		1,354,601	7,197,916
Current liabilities			
Trade and other payables		1,016,991	941,058
Provisions	5	731,850	275,123
Total current liabilities		1,748,841	1,216,181
Total liabilities		1,748,841	1,216,181
Net (liabilities)/assets		(394,240)	5,981,735
Equity			
Issued capital	6	92,102,583	89,519,207
Option reserves		8,296,835	8,166,905
Foreign currency translation reserve		4,724	4,724
Accumulated losses		(100,798,382)	(91,709,101)
Total (deficiency)/equity		(394,240)	5,981,735

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity for the year ended 30 June 2026

	Issued Capital \$	Option Reserve \$	Foreign currency translation reserve \$	Accumulated losses \$	Total \$
Balance at 1 July 2024	81,624,596	7,906,430	4,724	(82,318,515)	7,217,235
Loss for the year	-	-	-	(9,390,586)	(9,390,586)
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive income/(loss) for the year	-	-	-	(9,390,586)	(9,390,586)
Issue of ordinary shares (refer to note 6)	8,416,875	-	-	-	8,416,875
Share issue costs	(522,264)	-	-	-	(522,264)
Share based payments	-	260,475	-	-	260,475
Balance at 30 June 2025	89,519,207	8,166,905	4,724	(91,709,101)	5,981,735
Balance at 1 July 2025	89,519,207	8,166,905	4,724	(91,709,101)	5,981,735
Loss for the year	-	-	-	(9,089,281)	(9,089,281)
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive income/(loss) for the year	-	-	-	(9,089,281)	(9,089,281)
Issue of ordinary shares (refer to note 6)	2,704,000	-	-	-	2,704,000
Share issue costs	(120,624)	-	-	-	(120,624)
Share based payments	-	129,930	-	-	129,930
Balance at 30 June 2026	92,102,583	8,296,835	4,724	(100,798,382)	(394,240)

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Consolidated statement of cash flows for the year ended 30 June 2026

	Note	Year ended	
		30 June 2026	30 June 2025
		\$	\$
Cash flows from operating activities			
Payments to suppliers and employees		(3,033,092)	(3,560,896)
Interest received		106,810	253,852
Research and development tax refund received		1,711,618	1,885,140
Development costs paid		(5,521,012)	(7,298,431)
Net cash (used in) operating activities		(6,735,676)	(8,720,335)
Cash flows from investing activities			
Payments to acquire intellectual property		-	(50,000)
		-	(50,000)
Cash flows from financing activities			
Proceeds from issue of equity instruments of the Company	6	2,704,000	8,136,935
Payment for share issue costs		(120,624)	(522,264)
Net cash provided by financing activities		2,583,376	7,614,671
Net (decrease) in cash and cash equivalents		(4,152,300)	(1,155,664)
Cash and cash equivalents at the beginning of the year		5,049,744	6,205,418
Effects of exchange rate changes on the balance of cash held in foreign currencies		(26)	(10)
Cash and cash equivalents at the end of the year		897,418	5,049,744

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Notes to the consolidated financial statements for the year ended 30 June 2026

Note 1. General information

Cynata Therapeutics Limited ("Cynata" or the "Company") and its controlled entities ("the Group") is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.

Note 2. Basis of preparation

The preliminary final report has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. The preliminary final report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

This preliminary final report has been prepared in accordance with ASX Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the Corporations Act 2001. As such, this preliminary final report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2025 and any ASX announcements made by the Company during the period.

Going concern

The preliminary final report has been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business. As at 30 June 2026, the Group had negative working capital of \$629,205 (2025: positive \$4,132,831) and in the year then ended incurred a loss after tax of \$9,089,281 (2025: \$9,390,586) and had net operating cash outflows of \$6,735,676 (2025: \$8,720,335). As at 30 June 2026, the Group had cash and cash equivalents of \$897,418 (2025: \$5,049,744) and net liabilities of \$394,240 (2025: net assets of \$5,981,735).

During the financial year, the Company announced the primary evaluations results of the Phase 2 clinical trial of CYP-001 in patients with aGvHD. While there was no safety concerns identified, with a similar adverse event profile between groups, there were also no significant differences between the control group and active groups in the primary or key secondary efficacy endpoints. Furthermore, the Company also announced top-line results of the Phase 3 trial of CYP-004 in osteoarthritis. Again, there were no safety concerns identified, with a similar adverse event profile between groups. However, there were also no statistically significant differences between the active and control groups in either of the co-primary endpoints, which assessed pain reduction and change in cartilage thickness, respectively, from baseline to 24 months. There was a substantial and durable reduction in knee pain intensity at all timepoints from 3-24 months compared to baseline (secondary endpoint), but no significant differences between groups at any timepoint.

The failure to demonstrate efficacy in the Phase 2 clinical trial of CYP-001 in aGvHD and the Phase 3 clinical trial of CYP-004 in osteoarthritis indicates that the economic performance of the Company's assets may be less positive than previously expected. Specifically, this relates to the value of the patents licensed to Cynata by WARF.

In light of the results of these 2 trials and subsequent to the year end, the board of Cynata made all of the Company's employee positions redundant to reduce costs significantly. It included the position of Chief Executive Officer and Managing Director and other key management personnel positions. Board members also agreed to waive their directors' fees effective 1 July 2026.

Subsequent to the year end, the Company entered into a Research and Development Tax Incentive (R&D TI) loan facility of \$600,000 with a commercial lender, secured against the assets of the Company including the anticipated FY26 R&D TI rebate (expected to be approximately \$1.7 million).

The Company has limited financial resources and does not currently generate operating revenue to fund material development activities. Its ability to execute its strategy, including maintaining and seeking to realise value from its existing technology and acquiring or in-licensing new development opportunities, will depend on careful management of its existing resources and access to additional funding. Such funding may include capital raisings, strategic transactions, partnering or licensing arrangements or other sources of funding.

The directors have reviewed the business outlook and cashflow forecasts, including the Group's expected expenditure and existing contractual obligations and have considered the funding initiatives available to the Group. On this basis, the directors consider that there are reasonable grounds to believe that the Company will be able to continue as a going concern. However, the matters described above, including the Group's limited financial resources, existing contractual obligations and dependence on obtaining additional funding, indicate the existence of a material uncertainty that may cast significant doubt on the Group's ability to continue as a going concern and, therefore, whether it will be able to realise its assets and discharge its liabilities in the normal course of business.

In the event that the Group is unable to obtain sufficient funding for on-going operational and capital requirements, there is material uncertainty that may cast significant doubt as to whether the Group will continue as a going concern and therefore proceed with realising its assets and discharging its liabilities in the normal course of business at the amounts stated in the financial report.

The preliminary final report do not include any adjustments relating to the recoverability or classification of recorded asset amounts or to the amounts or classification of liabilities that may be necessary should the Group not be able to continue as a going concern.

3. Product development costs

	2026 \$	2025 \$
Research and development expenses	4,963,636	6,565,975
Consultants	168,013	362,913
Travel and accommodation expenses	87,770	284,002
License fees	122,854	137,774
Patent costs	39,025	47,340
	5,381,298	7,398,004

4. Intangibles

	2026 \$	2025 \$
Carrying value at beginning of year (i)	1,848,904	1,851,868
Additions (ii)	-	280,000
Amortisation (iii)	(260,313)	(282,964)
Impairment charge (iv)	(1,353,626)	-
Net book value of research and development at end of year	234,965	1,848,904

(i) The carrying value at beginning of year represents the fair value attributable to interests in research and development of stem cells is due to, and in recognition of, the successful development activities and data generated by Cynata Incorporated as at the acquisition date (1 December 2013), representing progress toward the eventual commercialisation of the relevant technology less accumulated amortisation.

(ii) On 31 July 2024, Cynata issued 916,335 fully paid ordinary shares at a price of \$0.251 each for a value of \$230,000 to acquire wound dressing technology developed by TekCyte Limited. This technology is a core component of Cynata's Cymerus iPSC-derived MSC topical wound dressing product candidate, CYP-006TK. Cynata also paid \$50,000 cash in addition to the issue of the shares.

(iii) An amortisation expense of \$260,313 has been recognised in profit or loss (2025: \$282,964).

(iv) During the financial year, the Group carried out a review of the intangibles considering the results of the Phase 2 clinical trial of CYP-001 in aGvHD and the Phase 3 clinical trial of CYP-004 in osteoarthritis. The failure to demonstrate efficacy in the abovementioned trials indicates that the economic performance of the Company's assets may be less positive than previously expected. As a result of this review, the Group determined that the carrying value of these relevant intangible assets were impaired and recognised an impairment loss of \$1,353,626, reducing their carrying value to nil as at 30 June 2026. Specifically, this relates to the carrying value of the patents licensed to Cynata by WARF. The carrying value of the intellectual property rights acquired from TekCyte is unaffected by the recent aGvHD and osteoarthritis results, as those intellectual property rights are applicable only to the Company's wound dressing product.

5. Provisions

	2026 \$	2025 \$
Provisions for employee entitlements	285,054	275,123
Redundancy provisions (i)	446,796	-
	731,850	275,123

(i) On 6 July 2026, the Company announced substantial reductions in expenditure, including board and management changes and the establishment of a Research and Development Tax Incentive (R&D TI) loan facility. All of the Company's employee positions were made redundant including the positions of Chief Executive Officer and Managing Director, Chief Medical Officer and Chief Business Officer.

6. Issued capital

243,454,369 fully paid ordinary shares (2025: 225,954,369)

2026	2025
\$	\$
92,102,583	89,519,207

Fully paid ordinary shares

	30 June 2026		30 June 2025	
	No.	\$	No.	\$
Balance at beginning of year	225,954,369	89,519,207	179,631,786	81,624,596
Issue of shares (i)	-	-	3,150	945
Issue of shares (ii)	-	-	916,335	230,000
Issue of shares (iii)	-	-	125,000	25,000
Issue of shares (iv)	-	-	125,000	25,000
Placement (v)	-	-	44,444,445	8,000,000
Issue of shares (vi)	-	-	638,886	115,000
Issue of shares (vii)	-	-	69,767	20,930
Issue of shares (viii)	11,500,000	-	-	-
Set-off shares (ix)	(4,300,000)	-	-	-
Issue of set-off shares(x)	4,300,000	1,204,000	-	-
Issue of shares (xi)	6,000,000	1,500,000	-	-
Share issue costs	-	(120,624)	-	(522,264)
Balance at end of the year	243,454,369	92,102,583	225,954,369	89,519,207

(i) Exercise of listed 1 April 2025 options at \$0.30 each on 19 July 2024.

(ii) Issue of shares on 31 July 2024 pursuant to a Deed of Assignment of Intellectual Property Rights. Refer to note 12 for more information.

(iii) Issue of shares on 2 September 2024 in consideration for the first instalment for the provision of investor relations services.

(iv) Issue of shares on 8 November 2024 in consideration for the second instalment for the provision of investor relations services.

(v) Issue of shares on 16 December 2024 pursuant to an Institutional Placement at \$0.18 per share.

(vi) Issue of Director shares on 23 January 2025 pursuant to a participation of Directors in the Institutional Placement at \$0.18 per share.

(vii) Exercise of listed 1 April 2025 options at \$0.30 each on 20 February 2025.

(viii) Issue of shares on 21 August 2025 pursuant to the At-the-Market Subscription Agreement ("ATM") at nil consideration. The ATM provides Cynata with up to \$7,500,000 of standby equity capital over the coming five years to 31 July 2030. Cynata has full discretion as to whether to utilize the ATM, the maximum number of shares to be issued, the minimum issue price of shares and the timing of each subscription. The shares can be bought back at nil consideration at the expiry of the facility.

(ix) Set-off shares on 23 January 2026 pursuant to At-the-Market Subscription Agreement with Acuity Capital.

(x) Issue of Set-off shares on 23 January 2026 pursuant to At-the-Market Subscription Agreement with Acuity Capital at \$0.28 per share.

(xi) Issue of shares on 8 May 2026 pursuant to a Placement at \$0.25 per share.

7. Events after the reporting period

On 6 July 2026, the Company announced substantial reductions in expenditure, including board and management changes and the establishment of a Research and Development Tax Incentive (R&D TI) loan facility. All of the Company's employee positions were made redundant including the positions of Chief Executive Officer and Managing Director, Chief Medical Officer and Chief Business Officer. The R&DTI loan is for a total of \$600,000 and is secured against the Company's assets including its anticipated R&D TI rebate for the 2026 financial year.

On 6 July 2026, Dr Darryl Maher resigned as director of the Company.

Other than the above, there has not been any matter or circumstance occurring subsequent to the end of the financial year that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or state of affairs of the Group in future financial years.